Atwood, Brady K., Alex Straiker, and Ken Mackie, ‘CB2: Therapeutic Target-in-Waiting’, Progress in Neuro-Psychopharmacology and Biological Psychiatry, 38.1 (2012), 16–20 <https://doi.org/10.1016/j.pnpbp.2011.12.001>
Balon, Richard, ‘Mood, Anxiety, and Physical Illness: Body and Mind, or Mind and Body?’, Depression and Anxiety, 23.6 (2006), 377–87 <https://doi.org/10.1002/da.20217>
Brisbare-Roch, Catherine, ‘Promotion of Sleep by Targeting the Orexin System in Rats, Dogs and Humans’, 13.2 (2007), 150–55 <http://www.nature.com.libproxy.ucl.ac.uk/nm/journal/v13/n2/pdf/nm1544.pdf>
Carlos H. Schenck, Mark W. Mahowald, ‘Insights from Studying Human Sleep Disorders’, 437.7063 (2005), 1279–85 <http://www.nature.com.libproxy.ucl.ac.uk/nature/journal/v437/n7063/pdf/nature04287.pdf>
Carvalho, Ana Franky, and Elisabeth J. Van Bockstaele, ‘Cannabinoid Modulation of Noradrenergic Circuits: Implications for Psychiatric Disorders’, Progress in Neuro-Psychopharmacology and Biological Psychiatry, 38.1 (2012), 59–67 <https://doi.org/10.1016/j.pnpbp.2012.01.008>
Cera, Nicoletta, Armando Tartaro, and Stefano L. Sensi, ‘Modafinil Alters Intrinsic Functional Connectivity of the Right Posterior Insula: A Pharmacological Resting State fMRI Study’, PLoS ONE, 9.9 (2014) <https://doi.org/10.1371/journal.pone.0107145>
Cryan, John F., and Klemens Kaupmann, ‘Don’t Worry “B” Happy!: A Role for GABAB Receptors in Anxiety and Depression’, Trends in Pharmacological Sciences, 26.1 (2005), 36–43 <https://doi.org/10.1016/j.tips.2004.11.004>
Eric J. Olson, Kannan Ramar, ‘Management of Common Sleep Disorders’, 88.4 (2013), 231–38 <http://www.aafp.org/afp/2013/0815/p231.pdf>
Freund, Tamás F, ‘Interneuron Diversity Series: Rhythm and Mood in Perisomatic Inhibition’, Trends in Neurosciences, 26.9 (2003), 489–95 <https://doi.org/10.1016/S0166-2236(03)00227-3>
H. Attarian, O Adenuga, ‘Treatment of Disorders of Hypersomnolence’, 16.9, 302–302 <http://download.springer.com/static/pdf/61/art%253A10.1007%252Fs11940-014-0302-9.pdf?auth66=1414068132_049751e80fe3aa485ba574ca1df01580&ext=.pdf>
Hill, Andrew J., Claire M. Williams, Benjamin J. Whalley, and Gary J. Stephens, ‘Phytocannabinoids as Novel Therapeutic Agents in CNS Disorders’, Pharmacology & Therapeutics, 133.1 (2012), 79–97 <https://doi.org/10.1016/j.pharmthera.2011.09.002>
Holmes, Andrew, Markus Heilig, Nadia M.J. Rupniak, Thomas Steckler, and Guy Griebel, ‘Neuropeptide Systems as Novel Therapeutic Targets for Depression and Anxiety Disorders’, Trends in Pharmacological Sciences, 24.11 (2003), 580–88 <https://doi.org/10.1016/j.tips.2003.09.011>
Hoyer, Daniel, and Laura H. Jacobson, ‘Orexin in Sleep, Addiction and More: Is the Perfect Insomnia Drug at Hand?’, Neuropeptides, 47.6 (2013), 477–88 <https://doi.org/10.1016/j.npep.2013.10.009>
Kalueff, Allan V., and David J. Nutt, ‘Role of GABA in Anxiety and Depression’, Depression and Anxiety, 24.7 (2007), 495–517 <https://doi.org/10.1002/da.20262>
Kilduff, Thomas S., and Christelle Peyron, ‘The Hypocretin/Orexin Ligand–Receptor System: Implications for Sleep and Sleep Disorders’, Trends in Neurosciences, 23.8 (2000), 359–65 <https://doi.org/10.1016/S0166-2236(00)01594-0>
Levine, Joseph, Daniel P. Cole, K. N. Roy Chengappa, and Samuel Gershon M.D., ‘Anxiety Disorders and Major Depression, Together or Apart’, Depression and Anxiety, 14.2 (2001), 94–104 <https://doi.org/10.1002/da.1051>
Luscher, B, Q Shen, and N Sahir, ‘The GABAergic Deficit Hypothesis of Major Depressive Disorder’, Molecular Psychiatry, 16.4 (2011), 383–406 <https://doi.org/10.1038/mp.2010.120>
Mahowald, Mark W., and Carlos H. Schenck, ‘Dissociated States of Wakefulness and Sleep’, Neurology, 42 Suppl. 6 (1992), 44–52 <http://ovidsp.uk.ovid.com/sp-3.29.1a/ovidweb.cgi?QS2=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>
Mark W. Mahowald MD, ‘Pathophysiologic Mechanisms in REM Sleep Behavior Disorder’, Current Neurology and Neuroscience Reports, 7.Issue 2 (2007), 167–72 <https://doi.org/10.1007/s11910-007-0013-7>
N.P. Robertson, K.J. Peall, ‘Narcolepsy: Environment, Genes and Treatment’, 261.8 (2014), 1644–46 <http://link.springer.com.libproxy.ucl.ac.uk/article/10.1007/s00415-014-7435-3/fulltext.html>
Saper, Clifford B., and Thomas E. Scammell, ‘Emerging Therapeutics in Sleep’, Annals of Neurology, 74.3 (2013), 435–40 <https://doi.org/10.1002/ana.24000>
Smith, Kiersten S., and Uwe Rudolph, ‘Anxiety and Depression: Mouse Genetics and Pharmacological Approaches to the Role of GABAA Receptor Subtypes’, Neuropharmacology, 62.1 (2012), 54–62 <https://doi.org/10.1016/j.neuropharm.2011.07.026>
‘Sodium Oxybate: A Primer for Pharmacists in the Treatment of Narcolepsy’ <https://www.researchgate.net/profile/Kimberley_Begley2/publication/265473606_Sodium_Oxybate_A_Primer_for_Pharmacists_in_the_Treatment_of_Narcolepsy/links/54dceb110cf25b09b912dd40.pdf>
Stores, G, ‘Medication for Sleep-Wake Disorders’, Archives of Disease in Childhood, 88.10 (2003), 899–903 <https://doi.org/10.1136/adc.88.10.899>
Strange, P. G., Brain Biochemistry and Brain Disorders (Oxford: Oxford University Press, 1992)